

## iv. Extra-pharmacopoeial drugs (Anukta dravya)

### iv. Extra-pharmacopoeial drugs (Anukta dravya) not finding place in Ayurvedic Classics

**Anukta Dravya** refers to **medicinal substances** absent from **classical Ayurvedic texts** (*Samhitā* or *Nighaṇṭu*) but found in **folk/traditional medicine**. Citing **Caraka Samhitā** (**Su. 27/330**):

यथा नानौषधं किञ्चिद्देशजानां वचो यथा ।  
द्रव्यं तत्तत्तथा वाच्यमनुकृतमिह यदभवेत् ॥

*"Even if a substance is not mentioned in the classics, if it is used by local people as medicine, it should be studied and validated."*

This underscores **Āyurveda's openness** to new knowledge, inviting comprehensive **study** of these "unspoken" drugs to **expand** and **adapt** its therapeutic repertoire.

#### Table Of Contents

Add a header to begin generating the table of contents

## Definition and Relevance of Anukta Dravya

### 1. Literal Meaning

- *Anukta* means "na-*ukta*"—not previously stated in classical scripture. Despite lacking direct references in \*Caraka, Suśruta, BhaiṣajyaRatnāvalī\* \*Caraka, Suśruta, BhaiṣajyaRatnāvalī\* \*Caraka, Suśruta, BhaiṣajyaRatnāvalī\* or **Nighaṇṭus**, such dravyas have **demonstrable therapeutic value** in local/folk contexts.

### 2. Need for Study

- **Ecological Diversity:** India's biodiversity includes **thousands** of medicinal plants beyond classical listings, many with robust **folk usage** for conditions like diabetes, cancer, or respiratory ailments.
- **Therapeutic Potential:** Modern diseases or region-specific ailments might benefit from these lesser-known species.
- **Scientific Validation:** Necessitates a systematic approach—**Rasapañcaka** analysis, phytochemical assays, pharmacological tests—to ensure safety and efficacy.

## Approach to Research and Validation

### 1. Identification and Documentation

- **Botanical Authentication:** E.g., morphological features, **DNA barcoding** for species like *Ghoda Tulasi* (*Scoparia dulcis*) to avoid misidentification.
- **TKDL (Traditional Knowledge Digital Library):** Recording local knowledge prevents bio-piracy and secures intellectual heritage.

### 2. Rasapañcaka Analysis

- Evaluating each *Anukta Dravya* through **Rasa** (taste), **Guṇa** (property), **Viṛya** (potency, ushna/śīta), **Vipāka** (post-digestive effect), and **Prabhāva** (unique effect).
- Aligns newly discovered or regionally used plants with classical dosha-based therapies.

### 3. Phytochemical Screening

- Extraction methods (Soxhlet, HPTLC fingerprinting, LC-MS) identify **marker compounds** (alkaloids, flavonoids, glycosides).
- E.g., *Ban Tambaku* (*Solanum erianthum*) might reveal new steroidal alkaloids beneficial for cough, asthma, or diabetes.

### 4. Pharmacological Studies

- **In vitro** and **in vivo** assays to confirm traditional claims (anti-inflammatory, antipyretic, anti-diabetic, immunomodulatory).
- Toxicity profiling (acute, sub-chronic) crucial if the drug's classical processing or detoxification steps are

absent.

#### 5. Integration into Pharmacopoeias

- On successful validation, the Ayurvedic Pharmacopoeia Committee (APC) or other bodies can add **monographs** in future expansions of the Ayurvedic Pharmacopoeia of India (API).
- Encourages uniform quality standards, fosters commercial cultivation, and widespread clinical use.

### Examples of Anukta Dravya

Below is a **representative** list of plants widely used in local/folk medicine but not found in classical Ayurvedic compendia:

| Local Name      | Botanical Name               | Traditional Indications  |
|-----------------|------------------------------|--|
| Raat ki Rani    | <i>Cestrum nocturnum</i>     | Spasm, heart disease   |
| Poinsetta       | <i>Euphorbia pulcherrima</i> | Tumor management, ornamental usage                                   |
| Ban Tambaku     | <i>Solanum erianthum</i>     | Inflammation, pain, cough, skin diseases, wounds, asthma, diabetes   |
| Jonkmari        | <i>Anagallis arvensis</i>    | Epilepsy, mania, hysteria, dropsy, leprosy                           |
| Nāgphūl         | <i>Gmelina asiatica</i>      | Syphilis, gonorrhea, eye burns, dysuria, dandruff                    |
| Rangoon ki bel  | <i>Quisqualis indica</i>     | Diarrhea, fever, worm infestation, boils, ulcers                     |
| Ghoda Tulasi    | <i>Scoparia dulcis</i>       | Headache, toothache, cough, wounds, heart disease, hemorrhoids, etc. |
| Gulabbas        | <i>Mirabilis jalapa</i>      | Boils, syphilis, diabetes, edema, gonorrhea, tumors                  |
| Aarogyappacha   | <i>Trichopus zeylanicus</i>  | Fatigue, aging, debility, appetite stimulant                         |
| Khogar (Kaikar) | <i>Garuga pinnata Roxb.</i>  | Asthma, worm infestation, obesity, eye disease, snake bite, cough    |

### Challenges in Studying Anukta Dravya

#### 1. Lack of Classical References

- No direct guidelines on dosage, processing (śodhana), or anupāna (vehicle).
- Potential confusion in morphological identification or synonyms.

#### 2. Standardization Difficulties

- Variability in plant parts used, harvest timing, or folk recipe differences.
- May require advanced **pharmacognostic** and **chemical** standardization procedures.

#### 3. Toxicity Risks

- Absence of classical śodhana methods can lead to unresolved toxicity (e.g., *Euphorbia pulcherrima* if used incorrectly).
- Need for thorough acute/chronic toxicity and safe dose determination.

#### 4. Integration into Ayurveda

- Some Vaidyas or purists resist adopting non-classical substances.
- Gradual acceptance is possible through rigorous proof of safety and synergy with doṣa-based frameworks.

### Future Directions

#### 1. Collaborative Research

- Ethnobotanists, tribal healers, academic labs co-document folk usage, bridging to standard Rasaśāstra frameworks.
- Government bodies like NMPB (National Medicinal Plants Board) can promote cultivation trials.

#### 2. Clinical Trials

- Evaluate efficacy for modern diseases (e.g., *Trichopus zeylanicus* for chronic fatigue, *Mirabilis jalapa* for tumors).
- Follow **Schedule Y** guidelines (Drugs & Cosmetics Act) if intended for large-scale commercial introduction as new proprietary medicine.

#### 3. Pharmacopoeial Expansion

- Revised volumes of the **Ayurvedic Pharmacopoeia of India (API)** or new monographs specifically for anukta dravyas (like a "Supplementary Pharmacopoeia of Anukta Dravya").
- Updates in e-databases or synergy with **TKDL** to protect from biopiracy.

#### 4. Conservation



- Some *anukta dravya* might be rare or region-specific. Need for sustainable harvest, *ex situ* or *in situ* conservation, mapping endangered species.

## Conclusion

**Anukta dravyas—unlisted** in classical Ayurvedic texts yet widely deployed in local or folk traditions—signify a **dynamic frontier** in modern Ayurveda. Their **systematic research** (taxonomic, pharmacognostic, phytochemical, clinical) can **enrich** the Ayurvedic pharmacopoeia, bridging **traditional knowledge** with **evidence-based** modern healthcare. By **standardizing** these less-explored botanicals, respecting local usage insights, and aligning with classical *Rasapañcaka* logic, Ayurveda can **expand** its therapeutic repertoire—retaining time-honored philosophy while **innovating** for contemporary global health challenges.